GS 4182
Alternative Names: GS-4182Latest Information Update: 09 Sep 2024
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III HIV infections
Most Recent Events
- 20 Aug 2024 Phase-II/III clinical trials in HIV infections (Combination therapy) in Puerto Rico (PO) (NCT06544733)
- 20 Aug 2024 Phase-II/III clinical trials in HIV infections (Combination therapy) in USA (PO) (NCT06544733)
- 09 Aug 2024 Gilead Sciences plans a phase II/III trial for HIV infections (Combination therapy) (PO) in September 2024 (NCT06544733) (EudraCT2024-511054-50)